Related references
Note: Only part of the references are listed.HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
Xiaoying Shen et al.
SCIENTIFIC REPORTS (2020)
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
Fatima Laher et al.
PLOS MEDICINE (2020)
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa
Glenda E. Gray et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
HIV research in South Africa: Advancing life
G. Gray et al.
SAMJ SOUTH AFRICAN MEDICAL JOURNAL (2019)
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
Linda-Gail Bekker et al.
LANCET HIV (2018)
Variability at the FCGR locus: characterization in Black South Africans and evidence for ethnic variation in and out of Africa
R. Lassauniere et al.
GENES AND IMMUNITY (2016)
A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial
T. Hertz et al.
VACCINE (2016)
Genital inflammation, immune activation and risk of sexual HIV acquisition
Jo-Ann S. Passmore et al.
CURRENT OPINION IN HIV AND AIDS (2016)
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
Cecilia Rademeyer et al.
PLOS PATHOGENS (2016)
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition
Heather A. Prentice et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Human Leukocyte Antigen Diversity: A Southern African Perspective
Mqondisi Tshabalala et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial
Shuying S. Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Analysis of HLA A☆02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial
Andrew J. Gartland et al.
JOURNAL OF VIROLOGY (2014)
Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIVmac251 at Challenge Exposure
Monica Vaccari et al.
JOURNAL OF VIROLOGY (2013)
Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial
Raphael Gottardo et al.
PLOS ONE (2013)
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144
Merlin L. Robb et al.
LANCET INFECTIOUS DISEASES (2012)
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
Morgane Rolland et al.
NATURE (2012)
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The mechanism of action of MF59 - An innately attractive adjuvant formulation
D. T. O'Hagan et al.
VACCINE (2012)
The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study
Kimberly A. Powers et al.
LANCET (2011)
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
Derek T. O'Hagan
EXPERT REVIEW OF VACCINES (2007)
Share Paper
